At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 631 enrolled
Drug / intervention
Cadazolid +3 moredrug
Likely dose
Cadazolid 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD).
In Brief
A Phase 3 clinical trial evaluating Cadazolid, Vancomycin, and 2 other interventions for Clostridium Difficile Infection. Completed, enrolled 631 participants.
Detailed Summary
This clinical study is conducted to assess the efficacy of cadazolid compared to vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClostridium Difficile Infection
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartDec 2013
Primary CompletionMar 2017
Study CompletionMay 2017
TodayJul 2026
First PostedNov 14, 2013
Enrollment StartDec 12, 2013
Primary CompletionMar 9, 2017
Study CompletionMay 2, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.6 years ago
Interventions
Cadazoliddrug
Cadazolid 250 mg as oral suspension twice daily.
Vancomycindrug
Vancomycin 125 mg as oral capsules 4 times daily
Cadazolid-matching placebodrug
Placebo matching cadazolid and administered orally twice daily
Vancomycin-matching placebodrug
Placebo capsules matching vancomycin and administered orally 4 times per day